RBC Capital Maintains Outperform on BeOne Medicines, Raises Price Target to $451

Benzinga Newsdesk www.benzinga.com Positive 92.7%

Neg 0% Neu 0% Pos 92.7%

RBC Capital analyst Leonid Timashev maintains BeOne Medicines (NASDAQ:ONC) with a Outperform and raises the price target from $436 to $451.